Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Momelotinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Expanded access; Therapeutic Use
- Sponsors Gilead Sciences; Sierra Oncology
- 22 Aug 2018 According to a Sierra Oncology media release, the company has acquired the drug candidate momelotinib for myelofibrosis from Gilead Sciences
- 08 May 2018 Status changed from not yet recruiting to recruiting.
- 29 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.